
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing quinidine sulfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing quinidine are listed in tablet form, including extended-release tablets, and in capsule form only in combination with dextromethorphan. Single-ingredient quinidine sulfate capsules were FDA-approved in the past and are listed as discontinued in Drugs@FDA.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Quinidine is a class IA antiarrhythmic, also labeled for a form of malaria, taken by mouth; compounded preparations require a prescription and are not FDA-approved.
Quinidine sulfate is a class IA antiarrhythmic. In heart muscle it depresses the rapid inward sodium current, slowing depolarization; in malaria it acts mainly against the parasite inside red blood cells. Drugs@FDA lists quinidine sulfate tablets from Epic Pharma as a current prescription product, while other quinidine sulfate tablets, Quinidex extended-release tablets and quinidine gluconate injection are listed as discontinued; quinidine gluconate extended-release tablets remain listed for prescription use. The Epic Pharma tablet label covers conversion of atrial fibrillation or flutter, reducing relapse into atrial fibrillation or flutter, suppression of documented life-threatening ventricular arrhythmias, and life-threatening Plasmodium falciparum malaria. Quinidine sulfate is also combined with dextromethorphan in Nuedexta capsules for pseudobulbar affect. A prescriber may order quinidine compounded in a strength or form not manufactured. Compounded preparations are not FDA-approved and require a prescription.
The tablet label warns that active antiarrhythmic therapy for non-life-threatening arrhythmias has increased mortality in many trials; in a meta-analysis of quinidine used to maintain normal rhythm after atrial fibrillation, mortality was higher in quinidine-treated patients than in those not given active drug. Quinidine prolongs the QT interval and can cause torsades de pointes, especially with a slow heart rate or low potassium, magnesium or calcium. Do not take it if you are allergic to it, developed low-platelet purpura with quinidine or quinine, have complete heart block without a pacemaker, or have myasthenia gravis. Quinidine may as much as double digoxin levels, can increase warfarin's effect, and blocks the CYP2D6 enzyme. Cinchonism (ringing ears, hearing loss, blurred vision, confusion), diarrhea, blood disorders and liver injury can occur. Avoid large amounts of grapefruit. In pregnancy, use only if clearly needed (label); LactMed reports low milk levels but advises monitoring breastfed infants. For side effects, talk to your prescriber or pharmacist.
Quinidine depresses the rapid inward sodium current in cardiac muscle and Purkinje fibers, slowing phase 0 and reducing action potential amplitude; the label also describes vagolytic effects. Absolute bioavailability from sulfate tablets is about 70% (range 45 to 100%); protein binding is 80 to 88% in adults, mainly to alpha1-acid glycoprotein and albumin; elimination half-life is 6 to 8 hours in adults and 3 to 4 hours in children. Hepatic elimination via CYP3A4 yields hydroxylated metabolites, some with antiarrhythmic activity, chiefly 3-hydroxyquinidine. Urinary alkalinizers reduce renal elimination; amiodarone, cimetidine and ketoconazole raise levels; phenobarbital, phenytoin and rifampin lower them. Quinidine is not a CYP2D6 substrate but inhibits CYP2D6, converting extensive metabolizers to poor metabolizers and possibly blunting codeine and hydrocodone analgesia; it raises digoxin, procainamide and haloperidol levels. In Nuedexta (Otsuka), quinidine raises dextromethorphan levels by competitively inhibiting CYP2D6; that label contraindicates prolonged QT, congenital long QT syndrome, torsades history and heart failure, and StatPearls also describes this combination for pseudobulbar affect. Dosing per prescriber. Monitor ECG and QTc, potassium and magnesium, blood counts, liver tests, digoxin levels and INR.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth